Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01259453 · ClinicalTrials.gov registry record · Phase 4
Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules
A Phase 4 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 595
- Enrollment target
NCT01259453 is a Phase 4 study that has completed, run by Yale University. The registered enrollment target is 595 participants.
The verdict
NCT01259453, a Phase 4 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 595 participants
- Enrollment target
Study Summary
The investigators seek to provide immunization for individuals who are at high risk of contracting hepatitis B virus (HBV) infection because of their illicit drug use. The investigators will be using the syringe exchange programs (SEPs) in Hartford and Bridgeport, CT and Chicago, IL to contact high risk individuals and refer them for vaccination. The primary purpose of the study is to compare the standard schedule of hepatitis B vaccination at 0, 1, and 6 months to an accelerated schedule of vaccination at 0, 1, and 2 months. The investigators hypothesize that the accelerated scheduling will result in improved completion rates without significant loss in vaccine efficacy.
Interventions
- BIOLOGICAL Vaccination to prevent hepatitis B virus infection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 595 participants |
| Start Date | 2003-05 |
| Est. Completion | 2006-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01259453
The ClinicalTrials.gov registry entry for NCT01259453 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 595 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Vaccination to prevent hepatitis B virus infection is the first listed.
NCT01259453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01259453 about?
NCT01259453 is a clinical study titled "Hepatitis B Vaccination Through Syringe Exchange Programs: A Randomized, Controlled Trial of Vaccination Schedules". The investigators seek to provide immunization for individuals who are at high risk of contracting hepatitis B virus (HBV) infection because of their illicit drug use. The investigators will be using the syringe exchange programs (SEPs) in Hartford and Bridgeport, CT and Chicago, IL to contact high ...
What is the current status of trial NCT01259453?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 595 participants. The study started on 2003-05. Estimated completion is 2006-08.
What interventions are being tested in trial NCT01259453?
The interventions under investigation include: Vaccination to prevent hepatitis B virus infection (BIOLOGICAL).
Who is sponsoring clinical trial NCT01259453?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.